Assetmark, Inc Medpace Holdings, Inc. Transaction History

Assetmark, Inc

$30.5 Billion
Q1 2024

A detailed history of Assetmark, Inc transactions in Medpace Holdings, Inc. stock. As of the latest transaction made, Assetmark, Inc holds 176 shares of MEDP stock, worth $71,392. This represents 0.0% of its overall portfolio holdings.

Number of Shares

176

Previous 220 20.0%

Holding current value

$71,392

Previous $67,000 5.97%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 06, 2024	SELL	$284.87 - $413.31 $12,534 - $18,185	-44 Reduced 20.0%	176 $71,000
Q3 2022 Nov 01, 2022	SELL	$145.13 - $182.49 $15,238 - $19,161	-105 Reduced 32.31%	220 $35,000
Q2 2022 Aug 03, 2022	SELL	$130.2 - $168.03 $11,066 - $14,282	-85 Reduced 20.73%	325 $49,000
Q4 2021 Feb 14, 2022	SELL	$182.74 - $227.9 $2,923 - $3,646	-16 Reduced 3.76%	410 $89,000
Q2 2021 Aug 16, 2021	BUY	$158.62 - $194.3 $1,586 - $1,943	10 Added 2.4%	426 $75,000

Q1 2021 May 14, 2021	BUY	$132.02 - $168.26 $6,601 - $8,413	50 Added 13.66%	416 $68,000
Q4 2020 Feb 10, 2021	BUY	$109.38 - $149.19 $39,486 - $53,857	361 Added 7220.0%	366 $51,000
Q2 2020 Aug 11, 2020	SELL	$68.08 - $95.68 $136 - $191	-2 Reduced 28.57%	5 $0
Q1 2020 May 12, 2020	SELL	$61.71 - $101.95 $1,481 - $2,446	-24 Reduced 77.42%	7 $1,000
Q4 2019 Feb 11, 2020	BUY	$70.08 - $84.64 $140 - $169	2 Added 6.9%	31 $3,000
Q3 2019 Nov 13, 2019	BUY	$62.38 - $85.89 $1,185 - $1,631	19 Added 190.0%	29 $2,000
Q2 2019 Aug 14, 2019	BUY	$53.64 - $65.42 $214 - $261	4 Added 66.67%	10 $1,000
Q1 2019 May 14, 2019	BUY	$49.38 - $70.58 $296 - $423	6 New	6 $0

Others Institutions Holding MEDP

# of Institutions

622

Shares Held

25.1M

Call Options Held

154K

Put Options Held

117K

View Full List

About Medpace Holdings, Inc.

Ticker MEDP
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 31,099,900
Market Cap $12.6B
Description
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, bi...

More about MEDP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Assetmark, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Assetmark, Inc with notifications on news.

Account